Attention Deficit Disorder Clinical Trial
— AttLapse-TDAOfficial title:
Neural Mechanisms Underlying Attention Lapses in Adult Attention Deficit Disorder: Towards a Better Clinical Diagnosis
NCT number | NCT03948607 |
Other study ID # | 7248 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 10, 2019 |
Est. completion date | May 5, 2021 |
Verified date | April 2023 |
Source | University Hospital, Strasbourg, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
ADHD is a common disorder, leading to a significant disability that often persists in adulthood. ADHD is characterized by attentional disturbances that are difficult to asses with standard neuropsychological tests. Attention tends to stall after a certain time of fatigue (i.e. an attention lapse). The aim of this study is to study the electroencephalographic (EEG) characteristics of these attention lapses in a sustained attention task, comparing ADHD patients with healthy subjects.
Status | Completed |
Enrollment | 63 |
Est. completion date | May 5, 2021 |
Est. primary completion date | May 5, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Diagnosis of ADHD according to DSM-5 criteria by a psychiatrist with clinical experience with ADHD - aged 18 to 60 - having signed an informed consent - able to understand the objectives and the risks related to the research For Healthy controls - Absence of psychiatric disorder or neurological disease - Matched in sex, age (± 2 years) and level of study (± 2 years) to each ADHD patient Exclusion criteria: - treatment by Methylphenidate or amphetamine in the 3 months preceding the study - treatment by a psychotropic drug other than antidepressant SSRI: anti-depressant non-SSRI, antipsychotic, mood stabilizer, benzodiazepine or hypnotic daily intake - neurological pathology or neurological sequelae - history of head trauma with loss of consciousness of more than 15 minutes - Subject under the protection of justice - Subject under guardianship, curatorship - Subject in exclusion period (determined by previous or current study), - Impossibility to give the subject enlightened information (subject in emergency situation, difficulties of comprehension of the subject (for example mental retardation, illiteracy, subject not including French ...) |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Civil - service de Psychiatrie 2 | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Spectral amplitude of the alpha band (8-14 Hz) to the quantitative EEG during the period up to 20 seconds before the successful trials vs. missed trials (lapse). | In healthy subjects, EEG changes, including increased parieto-occipital activity in the alphas frequency band (8-14Hz), have been observed 20 seconds before lapse (O'Connell et al., 2009). The analysis of the evoked potentials associated with the stimuli presented just before the occurrence of the target stimulus, reveals that the amplitude of the P300 on the 5 trials preceding the target to be detected is significantly lower before an omission (lapse) than before a correct detection. | During EEG realized after the inclusion | |
Secondary | CNV difference between missed and successful trials | Time course analysis of electrophysiological markers (EEG) before an attention lapse : amplitude of the evoked potentials | During EEG realized after the inclusion | |
Secondary | CNV difference between missed and successful trials | Time course analysis of electrophysiological markers (EEG) after a successful test: amplitude of the evoked potentials and theta power (intensity in µV). | During EEG realized after the inclusion | |
Secondary | Association between EEG lapses markers, neuropsychological measures of attention, clinical scales and subjective mindwandering | Regression and correlation analyzes involving electrophysiological markers associated with attentional lapses (see main objective) | During EEG realized after the inclusion | |
Secondary | Association between EEG lapses markers, neuropsychological measures of attention, clinical scales and subjective mindwandering | Regression and correlation analyzes involving electrophysiological markers associated with neuropsychological attention test scores (TAP) | During EEG realized after the inclusion | |
Secondary | Association between EEG lapses markers, neuropsychological measures of attention, clinical scales and subjective mindwandering | Regression and correlation analyzes involving electrophysiological markers associated with clinical scales (self-report ASRS and WFIRS) | During EEG realized after the inclusion | |
Secondary | Association between EEG lapses markers, neuropsychological measures of attention, clinical scales and subjective mindwandering | Regression and correlation analyzes involving electrophysiological markers associated with subjective measures of mind wandering (ad hoc questionnaire) | During EEG realized after the inclusion | |
Secondary | EEG lapse markers according attentional subjective state | Frequency of lapses of attentional lapses (evoked potentials P3a and CNV, theta power) (intensity in µV), according to the attentional state described by the subjects during the evaluations during the task | During EEG realized after the inclusion | |
Secondary | EEG lapse markers according attentional subjective state | amplitude electrophysiological markers (EEG) of attentional lapses (evoked potentials P3a and CNV, theta power) (intensity in µV), according to the attentional state described by the subjects during the evaluations during the task | During EEG realized after the inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01883817 -
Effect of Omega-3 Fatty Acid on Cortical Function in ADHD
|
Phase 3 | |
Completed |
NCT03662763 -
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity
|
Phase 3 | |
Recruiting |
NCT01154686 -
Working Memory Training in College Students With Attention-Deficit Hyperactivity Disorder/Learning Disabilities
|
N/A | |
Unknown status |
NCT01130467 -
Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder
|
Phase 4 | |
Completed |
NCT04577417 -
Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD
|
||
Completed |
NCT06064942 -
Multiple Family Narrative Therapy for Chinese Families of Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT06030024 -
Efficacy of Repetitive Transcranial Magnetic Stimulation in Adult Attention Deficit Disorder
|
N/A | |
Completed |
NCT05096975 -
Personality Profile of Children and Adolescents With ADHD and With or Without Emotional Dysregulation
|
||
Completed |
NCT03852966 -
Better Sleep in Psychiatric Care - ADHD Pilot Study
|
N/A | |
Terminated |
NCT01730079 -
Near Infrared Spectroscopy in Children With Autism and ADHD
|
||
Completed |
NCT02062411 -
A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder
|
N/A | |
Completed |
NCT01000064 -
Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits
|
Phase 3 | |
Completed |
NCT00048360 -
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
|
Phase 3 | |
Completed |
NCT00776737 -
Studies of Measures of Attention
|
N/A | |
Recruiting |
NCT05243186 -
Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill
|
Phase 2/Phase 3 | |
Recruiting |
NCT05133284 -
Effectiveness of a Therapeutic Education Program in Improving Quality of Life of Children With ADHD and Their Parents
|
||
Completed |
NCT02635035 -
Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT
|
Phase 2 | |
Completed |
NCT01369459 -
Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder
|
Phase 1 | |
Recruiting |
NCT05406414 -
The Efficacy of a Transdiagnostic Sleep and Circadian Intervention for Patients With Mental Disorders and Sleep Problems
|
N/A | |
Not yet recruiting |
NCT06248229 -
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
|
Phase 4 |